Literature DB >> 36184346

Encouraging the elderly in China to receive the COVID-19 vaccine is the next necessary step.

Ning Li1, Qiwei Liang2, Shaodi Ma1, Scott Lowe3, Rachel Bentley3, John Patrick Nanola Uy4, Chenyu Sun5.   

Abstract

Entities:  

Year:  2022        PMID: 36184346      PMCID: PMC9428593          DOI: 10.1016/j.puhe.2022.08.011

Source DB:  PubMed          Journal:  Public Health        ISSN: 0033-3506            Impact factor:   4.984


× No keyword cloud information.
  2 in total

1.  Heterologous AD5-nCOV plus CoronaVac versus homologous CoronaVac vaccination: a randomized phase 4 trial.

Authors:  Jingxin Li; Lihua Hou; Xiling Guo; Pengfei Jin; Shipo Wu; Jiahong Zhu; Hongxing Pan; Xue Wang; Zhizhou Song; Jingxuan Wan; Lunbiao Cui; Junqiang Li; Yin Chen; Xuewen Wang; Lairun Jin; Jingxian Liu; Fengjuan Shi; Xiaoyu Xu; Tao Zhu; Wei Chen; Fengcai Zhu
Journal:  Nat Med       Date:  2022-01-27       Impact factor: 87.241

2.  Safety and immunogenicity of COVID-19 vaccination in patients with hepatocellular carcinoma (CHESS-NMCID 2101): A multicenter prospective study.

Authors:  Xiaolong Qi; Jitao Wang; Qiran Zhang; Jingwen Ai; Chuan Liu; Qianqian Li; Ye Gu; Jiaojian Lv; Yifei Huang; Yanna Liu; Dan Xu; Shubo Chen; Dengxiang Liu; Jinlong Li; Huiling Xiang; Jing Liang; Li Bian; Zhen Zhang; Luxiang Liu; Xuying Zhang; Wei Qin; Xiaodong Wang; Zhiyun Hou; Nina Zhang; Aiguo Zhang; Hongmei Zu; Yun Wang; Zhaolan Yan; Xiufang Du; Aifang Hou; Jiansong Ji; Jie Yang; Jiansheng Huang; Zhongwei Zhao; Shengqiang Zou; Hailei Ji; Guohong Ge; Qing-Lei Zeng; Wenhong Zhang
Journal:  J Med Virol       Date:  2022-07-26       Impact factor: 20.693

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.